Group items tagged

Key Topics Covered Value Based Pricing- Strength of Innovation Vs Fiscal Pressures Major therapy areas to shape up pharma business going forward Europe – Regulatory Pressures and Increasing Pro Generic Stance Will US fall to Pricing Pressures? Emerging Markets and their importance in Growth of Large Cap Pharma Global Pharma -Drugs Losing Patent Protection By 2017 Impact of patent expiry in w.r.t. 2012 total revenue thru 2017 Global Pharma Research Pipeline (PhII And PhIII)- 2013 Global Pharma Milestones in 2013 Roche: Breast Cancer Franchise And Actemra To Drive Near Term Growth, And Multiple Blockbusters In Pipeline To Take Care Of Long Term Growth GlaxoSmithKline: Next Generation Bronchodilators, Melanoma, Hiv And Emerging Market To Lead The Way While Regulatory Overhang In Respiratory And EU Pricing Pressure Persist Bristol-Myers Squibb: Pressures To Dominate In The Near Term, Pipeline Will Take Longer To Deliver AstraZeneca: 2013 Will Be A Transition Year And AZN May Have To Take Some Bold Initiatives Eli Lilly: Late Stage Pipeline Fickle And Risky Merck: News-flow from Mega-trial on MRK's cardiology Franchise would reshape Merck's Growth Prospects Novartis: Back on a Growth Trajectory Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec – The Future Drivers Pfizer: M&A Only Can Drive Further Upside In The Near Term Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About Global Pharma Sector Industry Tables

provides valuations and an in depth analyses of biotech companies, their launched drug portfolio and promising drug candidates in the pipeline.

Most of these costs, writes the author Avik Roy, have to do with one specific aspect of the pipeline - phase III

Overall, Phase III trials now represent about 40 percent of pharmaceutical companies' R&D expenditures.

Phase III trials have become bigger, more complicated, more restrictive, and more time consuming as the years pass. Why should this be so? Is medical technology really getting all that more complicated that progressively more restrictive phase III trials are the only thing standing between global health and a renegade pharmaceutical industry intent on poisoning the human race with wildly experimental drugs?

Anne O’Riordan, Global Industry Managing Director of Accenture’s Life Sciences group, believes that this offers an engine for return to growth.Moody’s Credit Outlook agree and in response they have upgraded their outlook for the Pharmaceutical Sector from Negative to Stable, pointing out that “the multiyear wave of drug patent expirations that have squeezed profits should subside next year”.

Global pharmaceutical company GlaxoSmithKline has been hugely successful at supporting a culture of innovation with smaller entrepreneurial units as well as developing strengths in the consumer health markets in the Middle East and Asia.

Bristol-Meyers Squibb has also developed a very specific strategy and targeted unmet clinical needs, such as biological dugs and oncology, as well as executed some creative deals with big pharma companies and implemented fundamental internal organisational changes.

MARCHÉ PHARMA: Vers une offre de service autour du médicament – IMS Health Publié le 17/06/2011 Sélectionner une langue​▼ Nouveaux marché émergents et stabilité en Europe, nouveaux segments de produits et surtout nouvelles exigences de l'ensemble des acteurs du système de santé, des Autorités sanitaires au patients en incluant aujourd'hui l'ensemble des professionnels de santé, le tout dans un contexte économique tendu, ce rapport d'IMS Health souligne, à destination des laboratoires pharmaceutiques, la nécessité d'adapter, en permanence, leurs stratégies marketing. On retiendra en particulier la notion de progrès médical dans l'innovation et de service autour du médicament qui doit désormais être intégrée dans l'offre pharmaceutique.

Des marchés émergents: Avec le tassement des marchés matures, les Etats‐Unis notamment devraient être remplacés par la Chine, prochain principal contributeur à la croissance mondiale avec le Brésil, la Russie, l'Inde, l'Asie du Sud‐Est et l'Amérique Latine.

Des pathologies émergentes: Cette étude publiée par IMS Health souligne, pour l'Europe, l'augmentation du segment des médicaments de spécialistes au dépens du segment des médicaments de généralistes.  Alzheimer, épilepsie,  Parkinson,  sclérose en plaques, ces grandes pathologies en neurologie devraient faire l'essentiel de la croissance du marché (7 % pour les « spécialistes », contre 5 % pour les « généralistes).

The cleverness of CP+B’s “More Than Medication” campaign is 50% in the content that’s there, and 50% in the content that isn’t. Missing are the saccharine smiles, ridiculous athletic feats and idyllic dalliances of perfectly healthy people that never took the medication they’re purporting to be endorsing. Rather than portraying people who could be anyone (or, sadly, no one), these ads are the antithesis. “More Than Medication” is about life—mundane, radiant, lifechanging, heartbreaking. Through all of these milestones, Pfizer is attempting to build relationships one person at a time, and be a valuable presence in their healthy lives at their most important stages. Only time will tell if the campaign pays dividends, but as advertising strategy, it’s brilliant. Pharmaceutical companies rely on wholescale batch assembly at every stage of development, from searching for molecules as drug candidates, to researching them, to the mass production thereof. In fact, the fermentation tanks developed by Pfizer that enabled the first-ever mass production of penicillin during World War II became a national historic landmark in 2008. This doesn’t dictate that pharmaceutical ads must follow the same standard operating protocol.

Beyond “reinventing” pharmaceutical advertising, the “More Than Medication” campaign taps into an important (and growing) wellness zeitgeist being embraced by the professional and private health care sectors. Within the last few years, emphasis has shifted significantly from medication to meditation, pills to pilates, and technology to tofu. Individual preventitive care, including eating habits, exercise, healthfulness beyond chemicals, and individual responsibility, has been gaining momentum as a critical component of modern medicine, nowhere more than in how it is advertised. Kaiser Permanente’s enormously successful and popular “Thrive” campaign, recently expanded to the tune of $53 million, has echoes the welness call to arms of Canada’s “More Than Medication” spots. Internal documents indicate that the 2004 campaign was launched to combat a declining membership of 150,000 in a similarly reviled industry (health insurance). The initially modest reach has since expanded to print, outdoors, television and radio.

Pfizer supplemented their television spots with an interactive website that offers resources for individuals and their families, including eating better, strengthening mind and body, practical life tips, and places to find help to achieve these goals. In doing do, the pharmaceutical behemoth rebrands themselves as in touch, personally connected on an individual level and convey that they care about their patients’ health even if it means never having to take one of their medications.

BIG R&D SPENDERS Company R&D Spend in Rs Crore Ranbaxy 331 Dr Reddys Labs 283 Sun Pharmaceutical 146 Wockhardt 94 Lupin 87 Cadila Healthcare 71 Torrent Pharmaceuticals 51 Biocon 27 Panacea Biotec 24  

GLOBAL BIOTECH R&D PRODUCTIVITY ON THE RISE The productivity of big pharma has been remarkable over the past 25 years. In each of the last 10 years, the pharmaceutical industry has ranked at the top of Fortune.s .most profitable. industry list. But this top ranking has eluded the industry in recent years, during which the productivity of the biotech sector. for many years poor in the aggregate.has strengthened markedly. An emerging distinction between biotech and big pharma is the productivity of R&D. According to Arthur D Levinson, chairman and CEO, Genentech, R&D spending by large pharmaceutical companies has been steadily increasing over time, while the number of new drug approvals (NDAs) coming out of these companies has been decreasing. In 2004, the pharmaceutical industry spent about $50 billion on R&D, compared to $16 billion spent on R&D by publicly traded US biotech companies, and an estimated $20 billion spent by the global biotech industry. In spite of its large R&D expenditures, big pharmas. NDAs have been declining steadily, while biotechs have accounted for an increasing share of NDAs over the past five years. In 2003, the biotech industry hit a milestone when it surpassed big pharma in the number of new drug approvals from the Food and Drug Administration (FDA) in a given year. The trend continued to favor biotech in 2004. In 2005, an estimated 35 new pharmaceutical or biotechnology products with sales potential of at least $150 million each will enter the market. Of these, 20 are expected to be products from biotechnology companies, and will be marketed directly by these companies or in collaboration with pharmaceutical partners. In addition, there are more than 700 compounds from biotech firms at various stages of development, with more than 400 compounds in clinical trials. More than four out of five therapies currently in drug development are founded on biotech discoveries or employ biotech tools.                                                                                                       Source: Ernst & Young

For the pharmaceutical industry, social media poses concerns that range from release of propriety information to regulatory constraints to patient safety. These concerns have limited the industry’s use of a potential marketing and networking tool. Other industries are using Twitter, Facebook, and other social media outlets to promote products, follow consumer trends, and connect directly with their consumers. Is social media being used effectively at all in the pharmaceutical industry? Are there ways social media can be positively used by industry members to share ideas, connect with industry members, or even promote products? And if there is a fear of regulatory infractions, what can or should FDA and other international regulatory agencies do to promote the use of social media?

Emerging markets offer the biggest growth – their market share is set to rise to 40% by 2016. The market for pharmaceutical products will grow on average by 4.5% annually until 2016. But growth in emerging markets will increase by almost 12%. China, Brazil, India and Russia (the so-called BRIC economies) in particular are experiencing high growth.

Code of Pharmaceutical Practices"

Organization of Pharmaceutical Producers of India (OPPI)

branded (sponsored and monitored by a specific brand), non-branded (usually support groups, fundraisers or information-based platforms like WebMD), and healthcare professional communities

acebook, Twitter and YouTube, as well as blogs (sponsored and non-sponsored)

a lot of opportunity for more engagement and creating educational communities onlin

he Central and Eastern Europe (CEE) region is often cited as being one of Europe’s fastest growing economies.  The pharmaceutical sector has grown rapidly over the past decade, and ranks within the top 10 industrial sectors in CEE. Its position has also been strengthened by the recent accessions of many CEE countries to the EU. The CEE pharmaceutical market has attracted many foreign investors in recent years, due to the strong opportunities for growth that exist here

great opportunity as well as some challenges

This year there were two major factors which contributed to Johnson & Johnson’s number one ranking. It successfully brought to market Abiraterone (Zytiga) - a lyase and steroid synthesis inhibitor for use in the treatment of prostate cancer - and furthermore it was a major riser in the Access to Medicine Index, which is of increasing global importance.”

“Roche, which kept its number 3 spot on the Index, saw the first combined launch of a drug and companion diagnostic device, but on the negative side it had to close phase III development of dalcetrapib, a potentially $20bn product. “Sanofi, although rising one place to rank fifth, suffered a massive climbdown with Zaltrap in colorectal cancer launching at a suicidally high price which it continued to defend against increasing criticism. It eventually cut costs to 50 per cent but the damage had been done. “And AstraZeneca is the perfect example of a company which has shown all the signs of panic over the past five years. The stress of an underwhelming pipeline has led it to make bad decisions on top of bad decisions, and although it enjoyed some top line growth by flogging its sales model, the same primary care sales model has led to poor decisions in many areas.”

hat’s based on less patent exposure, improving pipelines, growing contributions from emerging markets, and cost cutting.

a new publicly traded company AbbVie Incorporated (ABBV).

XIENCE, ABSORB and MitraClip should drive the growth.

This system is extremely beneficial for people suffering from complex coronary anatomy

In fact, many patient groups referred to negative press to explain why they downgraded their opinion of some drugmakers, particularly concerning patient safety, transparency and corporate integrity. Drugmakers with a high exposure to ‘bad stories’ in 2012 saw their rankings drop, PatientView writes in its report. Others benefited as a result.

But now the drugs in the headlines are generics. As the industry has grown and matured, it's faced greater scrutiny from regulatory agencies. Now it faces many of the same setbacks that plague their branded brethren.

Lipitor, Plavix, Lexapro and Seroquel

these same manufacturers are facing a patent cliff of their own